Endo Pharmaceuticals CFO Resigns
September 4, 2008
Endo Pharmaceuticals, which engages in the research, development, sale and marketing of branded and generic prescription pharmaceuticals, has announced that executive vice president and CFO, Charles Rowland, Jr, has resigned effective immediately, to pursue other interests.
Endo Pharmaceuticals has engaged an executive search firm to assist in the search for a new CFO.
David Holveck, president and CEO of Endo Pharmaceuticals, said: “The board and I wish to express our gratitude to Charlie for his contributions and service and wish him well in his future endeavors.”